Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 15 de 15
1.
G Ital Dermatol Venereol ; 155(4): 500-504, 2020 Aug.
Article En | MEDLINE | ID: mdl-33050682

Eccrine porocarcinoma is a rare skin cancer that originates from the acrosyringium of eccrine sweat glands. From the clinical point of view the differential diagnosis with other skin cancers such as basal cell carcinoma and squamous cell carcinoma it is often impossible, only the histopathologic features can lead to the definitive diagnosis. Eccrine porocarcinoma can arise from a previous poroma or de novo, it may recur after surgical excision and cause lymph node and visceral metastasis. There are no international guidelines for treatment or follow-up of patients. The aim of this work was to present a rare case of eccrine porocarcinoma of the scalp successfully treated in our clinic and to extrapolate from the international literature the main clinical and histopathological features of eccrine porocarcinoma and the various experiences regarding the types of treatment.


Eccrine Porocarcinoma/diagnosis , Scalp/pathology , Sweat Gland Neoplasms/diagnosis , Aged, 80 and over , Eccrine Porocarcinoma/pathology , Eccrine Porocarcinoma/therapy , Humans , Male , Sweat Gland Neoplasms/pathology , Sweat Gland Neoplasms/therapy
3.
Dermatol Surg ; 44(10): 1247-1261, 2018 10.
Article En | MEDLINE | ID: mdl-29894433

BACKGROUND: Eccrine porocarcinoma (EPC) is a rare cutaneous neoplasm with high potential for morbidity and mortality. Due to its rarity, there is a paucity of data profiling diagnosis, work-up, and management. OBJECTIVE: To consolidate reported information on demographics, diagnostics, clinical behavior, treatment modalities, and patient outcomes in EPC to provide a reference tool to optimize diagnosis and management. METHODS: A comprehensive PubMed search was performed from 1963 to November 2017 using PRISMA guidelines. This yielded 155 articles detailing 206 cases of porocarcinoma. RESULTS: Eccrine porocarcinoma most often presents in elderly patients on the head and neck or lower limbs. Metastatic disease at presentation is not uncommon (22%). Primary tumor location is significantly correlated with presence of metastasis (p = .038). The most common treatment is excision followed by Mohs micrographic surgery (MMS), although the outcomes after MMS were superior to those after surgical excision. CONCLUSION: This systematic review of individual patient data reveals that all patients should have a histological diagnosis with imaging considered for high-risk cases. Primary tumor location should also be considered in diagnostic and therapeutic decision-making. Although wide local excision (WLE) is currently the first-line treatment, MMS is becoming increasingly used, with evidence indicating improved outcomes as compared to those seen with WLE.


Eccrine Porocarcinoma/diagnosis , Eccrine Porocarcinoma/therapy , Sweat Gland Neoplasms/diagnosis , Sweat Gland Neoplasms/therapy , Aged , Eccrine Porocarcinoma/epidemiology , Female , Humans , Male , Middle Aged , Sweat Gland Neoplasms/epidemiology
5.
Actas Dermosifiliogr ; 108(4): e27-e32, 2017 May.
Article En, Es | MEDLINE | ID: mdl-28110827

Eccrine porocarcinoma is a rare, malignant cutaneous adnexal tumor that arises from the ducts of sweat glands. Found mainly in patients of advanced age, this tumor has diverse clinical presentations. Histology confirms the diagnosis, detects features relevant to prognosis, and guides treatment. Growth is slow, but the prognosis is poor if the tumor metastasizes to lymph nodes or visceral organs. We report 7 cases of eccrine porocarcinoma, describing patient characteristics, the clinical and histopathologic features of the tumors, and treatments used. Our observations were similar to those of other published case series. Given the lack of therapeutic algorithms or protocols for this carcinoma, we propose a decision-making schema based on our review of the literature and our experience with this case series. The algorithm centers on sentinel lymph node biopsy and histologic features.


Eccrine Porocarcinoma , Sweat Gland Neoplasms , Adult , Aged , Aged, 80 and over , Clinical Decision-Making , Disease Management , Eccrine Porocarcinoma/diagnosis , Eccrine Porocarcinoma/pathology , Eccrine Porocarcinoma/secondary , Eccrine Porocarcinoma/therapy , Female , Humans , Lymph Node Excision , Lymphatic Metastasis/diagnostic imaging , Male , Middle Aged , Prognosis , Radiotherapy, Adjuvant , Sentinel Lymph Node Biopsy , Sweat Gland Neoplasms/diagnosis , Sweat Gland Neoplasms/surgery , Sweat Gland Neoplasms/therapy
6.
G Ital Dermatol Venereol ; 152(1): 66-70, 2017 02.
Article En | MEDLINE | ID: mdl-25236317

Eccrine porocarcinoma is a rare and aggressive skin neoplasm; only two cases of sarcomatoid differentiation have been reported. Whereas surgery is effective as first line treatment, optimal management of recurrent or metastatic porocarcinoma is not defined and needs multidisciplinary approach. Here we described the first reported case of metastatic sarcomatoid porocarcinoma. Our patient experienced multiple recurrences, mainly loco-regional, and was treated with a multidisciplinary treatment, involving surgery, radiotherapy, chemotherapy and target therapy, leading to a more than 4 years survival, from the first recurrence. We conclude that multidisciplinary approach in metastatic porocarcinoma must involve surgeon, radiotherapist and medical oncologist. The combination of local and systemic treatments can delay recurrence and prolong survival also in very aggressive cases.


Eccrine Porocarcinoma/therapy , Sarcoma/therapy , Sweat Gland Neoplasms/therapy , Antineoplastic Agents/administration & dosage , Cetuximab/administration & dosage , Combined Modality Therapy , Eccrine Porocarcinoma/pathology , Humans , Interdisciplinary Communication , Male , Middle Aged , Neoplasm Recurrence, Local , Sarcoma/pathology , Survival Rate , Sweat Gland Neoplasms/pathology
7.
J Med Case Rep ; 10(1): 319, 2016 Nov 10.
Article En | MEDLINE | ID: mdl-27832810

BACKGROUND: Malignant tumors arising from the vulva account for only 0.6 % of all cancers in female patients. The predominant histologic type, representing about 90 % of these malignancies, is squamous cell carcinoma. Eccrine porocarcinoma is a rare malignant tumor arising from sweat glands. The incidence of eccrine porocarcinoma is estimated at 0.005-0.01 % of all cutaneous tumors. To the best of our knowledge, only seven previous cases of vulvar eccrine porocarcinoma have been reported in the English-language literature. We present the case of a patient with eccrine porocarcinoma of the vulva, and we summarize the clinical features of this disease using seven previously reported cases. CASE PRESENTATION: A 54-year-old Japanese woman visited a local hospital complaining of fever and left vulvar pain for 2 months. An initial examination revealed a 1 × 1 cm, firm, ulcerative mass in the inner aspect of the left labium minorum. With a preoperative diagnosis of vulvar squamous cell carcinoma, we performed a radical local excision followed by bilateral inguinal lymphadenectomy. Histological examination showed eccrine porocarcinoma, stage IB (T1bN0M0). Radiation therapy with weekly cisplatin administration was then given as adjuvant therapy. One month after treatment was completed, computed tomography revealed multiple metastases in the bilateral lungs and in the sacral bone. The patient received three courses of chemotherapy (paclitaxel and carboplatin) and underwent palliative radiation therapy to the sacrum. She died of her disease 12 months after surgery. CONCLUSIONS: We report the case of a patient with eccrine porocarcinoma of the vulva and summarize the clinical features and the treatment options of eccrine porocarcinoma from a few retrospective case reports. Although eccrine porocarcinoma is a rare disease, clinicians and pathologists should be aware of its clinical and histological features and its biological behavior.


Eccrine Porocarcinoma/pathology , Sweat Gland Neoplasms/pathology , Vulva/pathology , Vulvar Neoplasms/pathology , Drug Therapy, Combination , Eccrine Porocarcinoma/therapy , Fatal Outcome , Female , Fever , Humans , Middle Aged , Pain , Sweat Gland Neoplasms/therapy , Vulvar Neoplasms/therapy
8.
Gan To Kagaku Ryoho ; 43(12): 2016-2018, 2016 Nov.
Article Ja | MEDLINE | ID: mdl-28133207

An 80's woman was diagnosed with eccrine porocarcinoma of the head in 2010.T he tumor was removed surgically but relapsed in the cervical and axillary lymph nodes 2 years later.The patient underwent surgery, and received systemic chemotherapy and radiation.Chest CT after treatment revealed an irregular mass and thickened skin in the left breast.Core needle biopsy specimens were used to diagnose metastasis of eccrine porocarcinoma.A wide excision with a 1 cm margin was performed under local anesthesia.After surgery, supraclavicular lymph node recurrence was detected.The patient received palliative care because there was no effective treatment available.Eccrine porocarcinoma is a rare malignant tumor of the intraepidermal sweat duct.Breast metastasis from malignant disease is also rare.To our knowledge, breast metastasis of eccrine porocarcinoma has not been reported.


Breast Neoplasms/therapy , Eccrine Porocarcinoma/therapy , Sweat Gland Neoplasms/pathology , Sweat Gland Neoplasms/therapy , Aged, 80 and over , Breast Neoplasms/secondary , Chemoradiotherapy , Female , Humans , Lymphatic Metastasis , Treatment Outcome
10.
Facial Plast Surg Clin North Am ; 21(1): 43-53, 2013 Feb.
Article En | MEDLINE | ID: mdl-23369588

Nonmelanoma skin cancer (NMSC) is the most common form of malignancy in humans. The incidence of NMSC continues to increase despite increased awareness and sun-protective measures. If neglected or mismanaged, NMSC can cause significant morbidity and even death. The most common forms of NMSC on the head and neck include basal cell carcinoma, squamous cell carcinoma, sebaceous carcinoma, eccrine porocarcinoma, Merkel cell carcinoma, atypical fibroxanthoma, and microcystic adnexal carcinoma. Surgery is the mainstay of treatment (standard excision, Mohs micrographic surgery, curettage); however, other modalities exist, including radiation, topical immunomodulators, photodynamic therapy, and new systemic medications.


Carcinoma, Basal Cell/diagnosis , Carcinoma, Basal Cell/therapy , Carcinoma, Merkel Cell/diagnosis , Carcinoma, Merkel Cell/therapy , Carcinoma, Skin Appendage/diagnosis , Carcinoma, Skin Appendage/therapy , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/therapy , Eccrine Porocarcinoma/diagnosis , Eccrine Porocarcinoma/therapy , Fibroma/diagnosis , Fibroma/therapy , Sebaceous Gland Neoplasms/diagnosis , Sebaceous Gland Neoplasms/therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/etiology , Carcinoma, Merkel Cell/epidemiology , Carcinoma, Merkel Cell/etiology , Carcinoma, Skin Appendage/epidemiology , Carcinoma, Skin Appendage/etiology , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/etiology , Eccrine Porocarcinoma/epidemiology , Eccrine Porocarcinoma/etiology , Fibroma/epidemiology , Fibroma/etiology , Humans , Risk Factors , Sebaceous Gland Neoplasms/epidemiology , Sebaceous Gland Neoplasms/etiology , Skin Neoplasms/epidemiology , Skin Neoplasms/etiology
12.
Ann Dermatol Venereol ; 139(3): 194-8, 2012 Mar.
Article Fr | MEDLINE | ID: mdl-22401684

BACKGROUND: Giant skin tumours are defined as greater than 10 cm in size and are frequently a consequence of neglect. We report three cases of giant skin tumours and discuss possible factors associated with delayed diagnosis and treatment. OBSERVATIONS: Two men and one woman, aged 52, 62 and 78 years, presented with giant skin tumours. One was mentally retarded, one had a borderline personality and another was presenting a major depressive disorder. Pain, smell, bleeding and/or loss of function forced the patients to seek medical care. Tumour sizes were 11 to 30 cm and were present for between six months and 20 years. All patients had hidden their lesion from their doctor and families. In one case, a sebaceous carcinoma of the right shoulder required amputation of the right upper limb. In a second, palliative surgery and medical care was given for a metastatic porocarcinoma. The last patient received neoadjuvant chemotherapy for an undifferentiated carcinoma. DISCUSSION: Neglected skin tumours continue to be encountered even in 2011. Consultation was delayed due to fear of the diagnosis and/or lack of corresponding physicians, resulting in worsening of the prognosis. A larger scale study could help us to identify the factors associated with neglected giant tumours and to improve their management.


Skin Neoplasms/pathology , Tumor Burden , Aged , Amputation, Surgical , Antineoplastic Agents/therapeutic use , Borderline Personality Disorder/diagnosis , Borderline Personality Disorder/psychology , Carcinoma/diagnosis , Carcinoma/pathology , Carcinoma/psychology , Carcinoma/therapy , Delayed Diagnosis , Denial, Psychological , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/psychology , Disease Progression , Eccrine Porocarcinoma/diagnosis , Eccrine Porocarcinoma/pathology , Eccrine Porocarcinoma/psychology , Eccrine Porocarcinoma/therapy , Female , Genital Neoplasms, Male/diagnosis , Genital Neoplasms, Male/pathology , Genital Neoplasms, Male/therapy , Humans , Illness Behavior , Intellectual Disability/diagnosis , Intellectual Disability/psychology , Male , Middle Aged , Neoadjuvant Therapy , Palliative Care , Sebaceous Gland Neoplasms/diagnosis , Sebaceous Gland Neoplasms/pathology , Sebaceous Gland Neoplasms/psychology , Sebaceous Gland Neoplasms/therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/psychology , Skin Neoplasms/therapy
...